Form 4: Tyra Biosciences Director Susan Moran Receives Equity Compensation Through Stock Option Grant

Tyra Biosciences, Inc. Director Susan Moran was granted 22,200 stock options with an exercise price of $9.25 as part of the company's Non-Employee Director Compensation Program.

Summary

• Susan Moran, a Director of Tyra Biosciences, Inc. (TYRA), was granted 22,200 stock options on May 29, 2025.
• The options have an exercise price of $9.25 per share and an expiration date of May 28, 2035.
• This grant was made pursuant to the Issuer's Non-Employee Director Compensation Program.
• The options will vest monthly, with 1/12th of the total shares vesting each month following the grant date of May 29, 2025.
• An accelerated vesting clause states that any remaining unvested portion will vest on the date of the next annual meeting of stockholders if it occurs prior to the first anniversary of the grant date, contingent on continuous service.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation grant to a director, which is a positive for corporate governance and incentive alignment, but does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of Tyra Biosciences.
• This is a standard practice for compensating non-employee directors, indicating a structured approach to corporate governance and incentive alignment.

Future Outlook

The vesting schedule of the stock options indicates a future increase in the director's beneficial ownership of Tyra Biosciences common stock, contingent on continued service and the exercise of these options.

Management Comments

• The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program.

Industry Context

The grant of stock options to non-employee directors is a common and widely accepted practice across publicly traded companies, particularly in the biotechnology sector, to attract and retain qualified board members and align their interests with those of shareholders.

Comparison to Industry Standards

• The compensation structure, involving stock option grants, is consistent with typical non-employee director compensation programs observed in the biotechnology and broader public company sectors.
• While specific comparable companies or projects are not detailed in this filing, such equity grants are standard for directors at companies like Moderna, BioNTech, or smaller biotech firms, aiming to incentivize long-term value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: No direct impact mentioned, but a well-governed company can indirectly benefit all stakeholders.

Next Steps

• Continued monthly vesting of the 22,200 stock options following May 29, 2025.
• Potential accelerated vesting of remaining unvested options upon the next annual meeting of stockholders, if it occurs before the first anniversary of the grant date.

Key Dates

Keywords

Tyra Biosciences, TYRA, SEC Form 4, Insider Transaction, Stock Option Grant, Director Compensation, Equity Compensation, Susan Moran, Corporate Governance